Clinical Trials Browser

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06305754 2026-04-02

MK-2870-009

Phase 3 Recruiting

520 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06788912 2026-03-31

MK-3475-01E

Phase 2 Recruiting

60 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT05319730 2026-03-20

MK-3475-06B

Phase 1/2 Recruiting

230 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT03258593 2026-03-17

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Phase 1 Completed

15 enrolled 21 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ

NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Phase 2 Active not recruiting

62 enrolled

CNS

Ependymoma, Medulloblastoma

NCT04568902 2025-10-23

Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Phase 1 Completed

33 enrolled

Breast

Breast Neoplasms

NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Phase 2 Active not recruiting

69 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

NCT03554473 2025-05-09

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Phase 1/2 Completed

37 enrolled 19 charts

Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Clinical Trials

TroFuse-022

MK-2870-009

MK-3475-01E

MK-3475-06B

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers